NXT Biologics, Inc.
Athens, GA
- UEI
- MB9ADR23X1L8
- CAGE
- 850V7
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2391 Lakewood Manor Dr, Athens, GA 30606, USA
- Website
- nxtbiologics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a vaccine to prevent pneumocystis pneumonia | National Institute of Allergy and Infectious Diseases (NIH) | $272,439 |
Quick answers
Is NXT Biologics, Inc. registered in SAM.gov?
Yes. NXT Biologics, Inc.'s SAM.gov registration is active through June 14, 2027.
What is NXT Biologics, Inc.'s most recent federal award?
NXT Biologics, Inc.'s most recent federal grant award is Development of a vaccine to prevent pneumocystis pneumonia (R41AI145416), from National Institute of Allergy and Infectious Diseases (NIH), on January 1, 2020.
On GovTribe
See NXT Biologics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors